LXEO
Lexeo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.76
+4.55%Oct 1, 2026, 13:00 UTC
Lexeo Therapeutics announced that an abstract on its LX2006 gene therapy has been accepted for oral presentation at the International Congress of Parkinson's Disease and Movement Disorders 2026, to be held October 4-8, 2026 in Seoul, Korea.
Source:Sep 29, 2026, 20:30 UTC
Lexeo Therapeutics completed its acquisition of Mantle Therapeutics through a merger of its subsidiary Magma Merger Sub with and into Mantle, with upfront consideration of $5.3 million in cash and $3.0 million in Lexeo common stock plus up to $1.0 million in additional cash and $12.0 million in milestone payments.
Sep 23, 2026, 12:00 UTC
Apertura Gene Therapy will provide Lexeo Therapeutics access to its TfR1 CapX AAV capsid technology for a program designed to treat Friedreich ataxia.
Source:Sep 22, 2026, 11:10 UTC
Key Stockholders holding approximately 76.1% of Mantle Therapeutics' outstanding capital stock agreed to vote their shares in favor of the Lexeo Therapeutics merger.
Sep 22, 2026, 11:00 UTC
Lexeo Therapeutics signed a definitive agreement to acquire Mantle Therapeutics Inc., adding new modalities designed to increase or replace frataxin in the brain.
Source:Sep 22, 2026, 11:00 UTC
Lexeo Therapeutics launched three new research collaborations to evaluate gene therapy sequential dosing after LX2006 treatment and explore cerebellar targeting in Friedreich ataxia.
Source:Aug 12, 2026, 00:00 UTC
Lexeo Therapeutics reported its Q2 2026 financial results, with a net loss of $25.9 million and diluted EPS of -$0.30, and cash, cash equivalents and investments of $234.2 million as of June 30, 2026.
Aug 5, 2026, 11:00 UTC
The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lexeo Therapeutics for LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy, based on interim clinical data from an ongoing Phase I/II trial.
Source:Jun 15, 2026, 15:32 UTC
Lexeo Therapeutics announced a regulatory update regarding its pivotal SUNRISE-FA 2 trial for gene therapy candidate LX2006.
Source: